Letters, Testimony & Comments

December 21, 2007
Re: CMS-2238-P (Medicaid Program; Prescription Drugs) Dear Acting Administrator Weems: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare and Medicaid Services’ (CMS) Final...
December 10, 2007
BIO's comments on proposed changes to the 2010 HCPCS Level II Modification Process
December 6, 2007
Re: Comments on the USP Draft Medicare Model Guidelines Dear Dr. Perfetto: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the United States Pharmacopeia’s (USP) Draft Medicare Model Guidelines...
November 30, 2007
Letter from BIO suggesting agenda items for discussions at the next (6th) meeting of the working group on Access and Benefit Sharing in Geneva.
November 7, 2007
BIO's comments to AHRQ regarding the Guide to Conducting Comparative Effectiveness Reviews
November 5, 2007
The Biotechnology Industry Organization Presents a Luncheon Seminar: From Biotechnology Innovation to Global Health Solutions: Solutions for Diseases Affecting Developing Countries Wednesday, 07 November 2007 13h00 to 15h00 Pavilion of...
October 30, 2007
The Comments of the Biotechnology Industry Organization on the United States Patent & Trademark Office Proposed Rule Changes Concerning Biological Deposits April 21, 2008 Comments to Proposed Rulemaking Entitled: Revision to the Time for...
October 27, 2007
BIO addresses concerns to FASB’s Staff Position on accounting for instrument C and conventional convertible debt.
October 26, 2007
BIO's comments regarding the Effectiveness and Off-Label Use of Recombinant Factor VIIa
October 25, 2007
Dear Speaker Pelosi, Rep. Obey, Rep. Lewis, and Rep. Walsh, On behalf of the undersigned organizations, representing the life sciences industry in California and nationwide, we urge you to support a funding level for the National Institutes of...
October 24, 2007
The Biotechnology Industry Organization (BIO) appreciates this opportunity to provide the perspective of its members on the role of federally-funded university research in the patent system. BIO represents over 1,100 companies, universities and...
October 17, 2007
COMMENTS OF THE BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO) ON ISSUES TO BE ADDRESSED BY THE TECHNICAL EXPERTS GROUP ON CONCEPTS, TERMS, WORKING DEFINITIONS AND SECTORAL APPROACHES Introduction: Decision IX/12 of the Ninth Session of the Conference...
October 9, 2007
Attention: Kathleen Fonda Comments to Notice of Proposed Rulemaking Entitled: Examination of Patent Applications That Include Claims Containing Alternative Language Dear Ms. Fonda: The Biotechnology Industry Organization (BIO) appreciates...